Allergy Diagnostics

Allergy Diagnostics

Global Allergy Diagnostics Market to Reach US$8.3 Billion by 2030

The global market for Allergy Diagnostics estimated at US$4.2 Billion in the year 2023, is expected to reach US$8.3 Billion by 2030, growing at a CAGR of 10.2% over the analysis period 2023-2030. Allergy Diagnostics Assay Kits, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Allergy Diagnostics Instruments segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 14.8% CAGR

The Allergy Diagnostics market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.5% CAGR.

Global Allergy Diagnostics Market - Key Trends & Drivers Summarized

Allergy diagnostics encompasses a range of tests and procedures used to identify allergic reactions and pinpoint specific allergens responsible for these reactions. Allergies occur when the immune system reacts to foreign substances, such as pollen, food, or pet dander, which are typically harmless to most people. The primary methods of allergy diagnostics include skin tests, blood tests, and challenge tests. Skin tests, such as prick tests or intradermal tests, involve exposing the skin to potential allergens and observing the reaction. Blood tests, like the radioallergosorbent test (RAST) and enzyme-linked immunosorbent assay (ELISA), measure the presence of specific antibodies (IgE) that the immune system produces in response to allergens. Challenge tests are conducted under medical supervision and involve introducing small amounts of allergens to the patient and monitoring for adverse reactions. These diagnostic tools are crucial for accurately diagnosing allergies and devising appropriate management and treatment plans.

Technological advancements have significantly improved the accuracy, efficiency, and convenience of allergy diagnostics. Modern diagnostic techniques leverage advanced immunoassays and molecular diagnostics to detect specific allergen components, offering a more detailed understanding of allergic sensitivities. Multiplex testing platforms allow for the simultaneous analysis of multiple allergens from a single blood sample, enhancing the comprehensiveness of diagnostic evaluations. Furthermore, innovations in point-of-care testing enable rapid and on-site allergy assessments, providing immediate results and facilitating timely clinical decisions. These advancements are particularly beneficial in pediatric allergy diagnostics, where non-invasive and quick procedures are preferred. The integration of digital health tools, such as electronic health records (EHRs) and mobile health applications also supports allergy diagnostics by streamlining data management, improving patient monitoring, and enhancing communication between patients and healthcare providers.

The growth in the allergy diagnostics market is driven by several factors, including the increasing prevalence of allergic diseases, rising awareness about allergy management, and advancements in diagnostic technologies. The global burden of allergic conditions, such as asthma, allergic rhinitis, and food allergies, is on the rise, necessitating effective diagnostic solutions to manage and treat these conditions. Growing public awareness and education about allergies have led to higher demand for diagnostic testing, as more individuals seek to identify and manage their allergic triggers. Technological innovations have made allergy diagnostics more accessible and accurate, encouraging healthcare providers to adopt these advanced tools in clinical practice. Additionally, supportive government initiatives and healthcare policies aimed at improving allergy care and management are bolstering market growth. The expansion of healthcare infrastructure and increased investment in research and development further contribute to the market`s positive trajectory. As these trends continue, the allergy diagnostics market is poised for significant growth, driven by the ongoing need for precise, efficient, and patient-centric diagnostic solutions.

Select Competitors (Total 100 Featured) -

• 3M Company
• Bausch & Lomb, Inc.
• ACON Laboratories, Inc.
• Awareness Technology, Inc.
• ALK-Abello A/S
• Allergy Therapeutics Plc
• Alpha Laboratories Ltd.
• Angsana Molecular & Diagnostics Laboratory Pte Ltd.
• Bausch Health Companies Inc.
• Alkor Bio Group
• ALLERGOPHARMA GmbH & Co. KG
• AESKU.Diagnostics GmbH & Co. KG
• AllerGenis, Inc.
• Astra Biotech GmbH
• Assure Tech. (Hangzhou) Co., Ltd

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.